EcoDrugPlus

Voltage-Dependent Calcium Channel Gamma-2 Subunit

Ensembl ID : ENSDCDG00000021542
Gene Symbol: LOC114794501
3 Cross references
249 Possible Orthologues:

Voltage-Dependent Calcium Channel Gamma-2 Subunit-Like

Ensembl ID : ENSDCDG00000017410
Gene Symbol: LOC114786188
3 Cross references
249 Possible Orthologues:

Voltage-Dependent Calcium Channel Gamma-3 Subunit-Like

Ensembl ID : ENSDCDG00000003764
Gene Symbol: LOC114785791
2 Cross references
192 Possible Orthologues:

Voltage-Dependent Calcium Channel Gamma-4 Subunit-Like

Ensembl ID : ENSDCDG00000026563
Gene Symbol: LOC114782934
3 Cross references
192 Possible Orthologues:

Voltage-Dependent Calcium Channel Gamma-4 Subunit-Like

Ensembl ID : ENSDCDG00000025724
Gene Symbol: LOC114770166
3 Cross references
168 Possible Orthologues:

Voltage-Dependent Calcium Channel Gamma-6 Subunit-Like

Ensembl ID : ENSDCDG00000025730
Gene Symbol: LOC114770167
3 Cross references
181 Possible Orthologues:

Voltage-Dependent Calcium Channel Gamma-7 Subunit-Like

Ensembl ID : ENSDCDG00000025720
Gene Symbol: LOC114770661
3 Cross references
189 Possible Orthologues:

Voltage-Dependent Calcium Channel Subunit Alpha-2/delta-1-Like

Ensembl ID : ENSDCDG00000030409
Gene Symbol: LOC114764347
3 Cross references
230 Possible Orthologues:

Xanthine Dehydrogenase

Ensembl ID : ENSDCDG00000001922
Gene Symbol: XDH
3 Cross references
212 Possible Orthologues:

Ensembl ID : ENSDCDG00000016691
Gene Symbol: -
Cross references: -
138 Possible Orthologues:

Ensembl ID : ENSDCDG00000014999
Gene Symbol: -
Cross references: -
150 Possible Orthologues:

Ensembl ID : ENSDCDG00000028191
Gene Symbol: -
Cross references: -
206 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).